Literature DB >> 32788173

YTHDF1 Promotes Gastric Carcinogenesis by Controlling Translation of FZD7.

Jingnan Pi1,2, Wen Wang1,2, Ming Ji3, Xiaoshuang Wang1,2, Xueju Wei1,2, Jing Jin3, Tao Liu4, Jiaqi Qiang1,2, Zhihong Qi5, Feng Li6, Yue Liu1,2, Yanni Ma1,2, Yanmin Si1,2, Yue Huo1,2, Yufeng Gao1,2, Yiying Chen1,2, Lei Dong7, Rui Su7, Jianjun Chen7, Shuan Rao8, Ping Yi4, Shuyang Yu5, Fang Wang9,2, Jia Yu9,2,10.   

Abstract

N6-methyladenosine (m6A) is the most prevalent internal RNA modification in mammals that regulates homeostasis and function of modified RNA transcripts. Here, we aimed to investigate the role of YTH m6A RNA-binding protein 1 (YTHDF1), a key regulator of m6A methylation in gastric cancer tumorigenesis. Multiple bioinformatic analyses of different human cancer databases identified key m6A-associated genetic mutations that regulated gastric tumorigenesis. YTHDF1 was mutated in about 7% of patients with gastric cancer, and high expression of YTHDF1 was associated with more aggressive tumor progression and poor overall survival. Inhibition of YTHDF1 attenuated gastric cancer cell proliferation and tumorigenesis in vitro and in vivo. Mechanistically, YTHDF1 promoted the translation of a key Wnt receptor frizzled7 (FZD7) in an m6A-dependent manner, and mutated YTHDF1 enhanced expression of FZD7, leading to hyperactivation of the Wnt/β-catenin pathway and promotion of gastric carcinogenesis. Our results demonstrate the oncogenic role of YTHDF1 and its m6A-mediated regulation of Wnt/β-catenin signaling in gastric cancer, providing a novel approach of targeting such epigenetic regulators in this disease. SIGNIFICANCE: This study provides a rationale for controlling translation of key oncogenic drivers in cancer by manipulating epigenetic regulators, representing a novel and efficient strategy for anticancer treatment. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/81/10/2651/F1.large.jpg. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32788173     DOI: 10.1158/0008-5472.CAN-20-0066

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  45 in total

Review 1.  Mapping the genomic diaspora of gastric cancer.

Authors:  Khay Guan Yeoh; Patrick Tan
Journal:  Nat Rev Cancer       Date:  2021-10-26       Impact factor: 60.716

2.  Chromobox 4 (CBX4) promotes tumor progression and stemness via activating CDC20 in gastric cancer.

Authors:  Wen Li; Honghui Chen; Zhenggen Wang; Jingjing Liu; Xinan Lei; Wen Chen
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 3.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

Review 4.  RNA N6-Methyladenine Modification, Cellular Reprogramming, and Cancer Stemness.

Authors:  Huarong Chen; Yifei Wang; Hao Su; Xiaoting Zhang; Hongyan Chen; Jun Yu
Journal:  Front Cell Dev Biol       Date:  2022-07-04

5.  N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.

Authors:  Zhang Meijing; Luo Tianhang; Yang Biao
Journal:  Front Cell Dev Biol       Date:  2022-06-15

6.  RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/β-catenin signaling.

Authors:  Yin Li; Hao Sheng; Feng Ma; Qiang Wu; Jianfang Huang; Qiang Chen; Lianghe Sheng; Xinghai Zhu; Xiaoxi Zhu; Meng Xu
Journal:  Cell Death Dis       Date:  2021-05-13       Impact factor: 8.469

7.  m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation.

Authors:  Jia-Xiang Zhang; Pei-Jie Huang; Da-Peng Wang; Wen-Yu Yang; Jian Lu; Yong Zhu; Xiao-Xiao Meng; Xin Wu; Qiu-Hai Lin; Hui Lv; Hui Xie; Rui-Lan Wang
Journal:  Mol Ther       Date:  2021-06-08       Impact factor: 11.454

Review 8.  Function and clinical significance of N6-methyladenosine in digestive system tumours.

Authors:  Junchao Huang; Yingjie Shao; Wendong Gu
Journal:  Exp Hematol Oncol       Date:  2021-07-10

9.  m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.

Authors:  Jianhao Li; Weiwei Wang; Yubing Zhou; Liwen Liu; Guizhen Zhang; Kelei Guan; Xichun Cui; Xin Liu; Maoxin Huang; Guangying Cui; Ranran Sun
Journal:  Front Cell Dev Biol       Date:  2021-07-02

10.  An m6A-Related Prognostic Biomarker Associated With the Hepatocellular Carcinoma Immune Microenvironment.

Authors:  Yingxi Du; Yarui Ma; Qing Zhu; Tongzheng Liu; Yuchen Jiao; Peng Yuan; Xiaobing Wang
Journal:  Front Pharmacol       Date:  2021-06-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.